Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H30O3 |
| Molecular Weight | 306.4397 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](O)C=C4C[C@@H](O)CC[C@]34C
InChI
InChIKey=OEVZKEVBDIDVOI-YSZCXEEOSA-N
InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-17,20-22H,3-9H2,1-2H3/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1
| Molecular Formula | C19H30O3 |
| Molecular Weight | 306.4397 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:29:19 GMT 2025
by
admin
on
Mon Mar 31 18:29:19 GMT 2025
|
| Record UNII |
Q0CZ537GC8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2697-85-0
Created by
admin on Mon Mar 31 18:29:19 GMT 2025 , Edited by admin on Mon Mar 31 18:29:19 GMT 2025
|
PRIMARY | |||
|
DTXSID201043225
Created by
admin on Mon Mar 31 18:29:19 GMT 2025 , Edited by admin on Mon Mar 31 18:29:19 GMT 2025
|
PRIMARY | |||
|
Q0CZ537GC8
Created by
admin on Mon Mar 31 18:29:19 GMT 2025 , Edited by admin on Mon Mar 31 18:29:19 GMT 2025
|
PRIMARY | |||
|
DB06257
Created by
admin on Mon Mar 31 18:29:19 GMT 2025 , Edited by admin on Mon Mar 31 18:29:19 GMT 2025
|
PRIMARY | |||
|
9818024
Created by
admin on Mon Mar 31 18:29:19 GMT 2025 , Edited by admin on Mon Mar 31 18:29:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
IN VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Status: 606 - Abandoned - No Statement Of Use Filed
|
||
|
ACTIVE MOIETY |
HE-2200 has been in phase II clinical trials for the treatment of inflammatory bowel diseases and multiple sclerosis. However, this research has been discontinued. The compound was originally developed by Virginia Commonwealth University (VCU), and licensed to Harbor BioSciences (formerly Hollis-Eden Pharmaceuticals).
|